Showing results (81-90 of 307) with videos related to
Sort By:
Pageof 31
The International Journal of Neuroscience|February 15, 2012
The UPDRS-8: a brief clinical assessment scale for Parkinson's diseaseRobert A Hauser, Kelly E Lyons, Rajesh PahwaNeurodegenerative Disease Management|December 3, 2025
Practices and perceptions around splitting of carbidopa/levodopa tablets: a survey of patients and neurologistsRamon L Rodriguez, Stuart H Isaacson, Yasar Torres-Yaghi, et al.JAMA Neurology|March 20, 2026
Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical TrialHubert H Fernandez, Stuart H Isaacson, Robert A Hauser, et al.Neurology and Therapy|May 15, 2021
Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and "OFF" Episodes: Results of a Randomized, Three-Way Crossover, Open-Label StudyFelix Agbo, Stuart H Isaacson, Ramon Gil, et al.Expert Review of Neurotherapeutics|July 24, 2018
Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson's disease: recommendations from an expert panelRajesh Pahwa, Stuart H Isaacson, Diego Torres-Russotto, et al.The Annals of Pharmacotherapy|September 20, 2007
Role of the pharmacist in the effective management of wearing-off in Parkinson's diseaseWilliam Simonson, Robert A Hauser, Anthony H V SchapiraNeurology|August 13, 2003
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PDRobert A Hauser, Jean P Hubble, Daniel D Truong, et al.Parkinsonism & Related Disorders|December 28, 2020
Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®)Robert A Hauser, Leonid Zeitlin, Stanley Fisher, et al.Current Neurology and Neuroscience Reports|July 10, 2007
Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatmentTheresa A Zesiewicz, Kelly L Sullivan, Robert A HauserClinical Parkinsonism & Related Disorders|June 9, 2025
Sedation and sleep safety of pimavanserin for Parkinsons's disease psychosis: Review and exploratory analysis of clinical study dataAna Berrio, Lambros Chrones, Victor Abler, et al.Pageof 31